BOSTON, Mass. – By Lee Han-soo/Korea Biomedical Review correspondent – After a prolonged period of uncertainty and disruption caused by the Covid-19 pandemic, the biotechnology industry is experiencing a remarkable resurgence.
The 2023 BIO International Convention kicked off its four-day run at the Boston Convention and Exhibition Center on Monday (local time), in Boston, Mass.
Organized by the Biotechnology Innovation Organization (BIO), this year's event will bring together more than 4,000 companies from 85 countries and around 14,000 attendees for a variety of business meetings and conferences.
This year’s BIO convention also shows Korea’s strong commitment and interest in the bio-field because President Yoon Suk Yeol set the bioindustry as the next major national growth engine and promised to support exports and ease regulations.
Reflecting such sentiment, the number of Korean companies and organizations participating in the BIO International Convention this year more than doubled from last year.
According to the Ministry of Trade, Industry and Energy, there were 544 participating companies this year, compared to 255 last year.
Major Korean companies (Samsung Biologics, Celltrion, Lotte Biologics, ST Pharm), smaller bio ventures (ABL Bio, CHA Biotech, Aptabio Therapeutics, Eubiologics, Prestige Biopharma, HLB), and hospitals (Seoul National University Hospital and Asan Medical Center) all joined BIO 2023.
Korean companies expressed their high expectations for significant achievements during the event. Their goals include making deals with multinational pharmaceutical companies or signing new contract development and manufacturing organization (CDMO) agreements.
Related articles
- [Special] Shaperon’s exclusive technology to fuel global expansion
- [Special] EuBiologics to spearhead ‘K-vaccine’ wave at BIO 2023
- Lotte Biologics to highlight commitment to high-quality services at BIO 2023
- [Special] Dong-A ST speeds up global entry with new drugs
- Samsung Biologics to participate in 2023 BIO International Convention
- Prestige Biopharma to attend BIO 2023
- CHA Biomedical Group seeks global biz expansion at BIO 2023
- [Special] Korean CDMO companies ready to wheel and deal at BIO 2023
- [Special] Which Korean companies will be most active at BIO 2023?
- Samsung Biologics’ Plant 5 will be ready 5 months earlier than scheduled: CEO
- Merck's BD team driven by science-backed data to address unmet needs
- Prestige Biopharma speeds up global expansion with tailored CDMO
- Samyang Holdings Biopharm to open biodegradable suture plant in Hungary
- ‘Korea's biopharma industry needs more Innovation to stand out among competitors’
- Yuhan USA prepares for ‘next Leclaza’ in bio’s mecca of Boston
- EuBiologics armed with vaccine expertise aims for ‘big deal’ with Big Pharma
- CRO Dream CIS emerges as top helper for K-Bio’s advance to US market
- Osteoarthritis drug maker YiPSCELL met future partners at BIO 2023
- US FDA OKs Huons’ 2% lidocaine for local anesthesia
- Prestige Biopharma joins Biden's 'Cancer Moonshot' to conquer pancreatic cancer